RxDoctor Payments Data

Michael McGill, MD

Cardiovascular Disease · Minocqua, WINPI 1629045638

Payments from drug & device makers

$510in general payments, 2019–2025

Across 23 payments — averaging $22.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$125
  • Novartis$66
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$65
  • Pfizer$60
  • E.r. Squibb & Sons, L.L.C.$42
  • Novo Nordisk$35
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$49096%
  • Education$204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$510 in reported general payments places this provider in the 40th percentile of 322 cardiovascular disease providers in Wisconsin.

See all cardiovascular disease providers in Wisconsin

Medicare billing

Part B allowed, 2024
$208,659
Medicare patients
2,178
Services billed
6,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban834$954,137
JardianceEmpagliflozin207$196,488
EntrestoSacubitril/Valsartan158$165,476
XareltoRivaroxaban91$122,468
MultaqDronedarone Hcl92$120,143
Repatha SureclickEvolocumab61$43,586
CorlanorIvabradine Hcl21$17,707
Praluent PenAlirocumab18$17,025
Repatha SyringeEvolocumab17$13,783
Dofetilide49$10,789
VascepaIcosapent Ethyl22$9,866
Metoprolol Succinate614$9,330
Ranolazine ErRanolazine77$8,819
Flecainide Acetate170$7,792
Potassium Chloride255$4,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$60$954,137834 claims
NovartisEntresto$66$165,476158 claims
Johnson & JohnsonXarelto$23$122,46891 claims
AmgenCorlanor$125$17,70721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 322 cardiovascular disease providers in Wisconsin.

Other cardiovascular disease in Minocqua

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →